Nasus Pharma Ltd (NSRX)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Last price
- $2.82
- As of
Kresmion compiles this page from NSRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Nasus Pharma Ltd (NSRX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-08.
See the full NSRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NSRX on one page. Preview it with sample data, then open it live with a free account.
Preview the NSRX dossierActive events for NSRX
- medium13F: new position
CITADEL ADVISORS LLC new position in NSRX
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in NSRX
FREE, NO ACCOUNT
Every event on NSRX, as it fires
New filings, 13F moves and cross asset events on NSRX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
NSRX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP M7071P109 · 2026Q2 | $77K | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP M7071P109 · 2026Q2 | $43K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NSRX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
Going concern statement
NSRX's 20-F filed Mar 25, 2026 states:
…which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining new financing on reasonable terms or at all.
Read the 20-F on SEC EDGAR Every company with a going concern statement
More data on NSRX
NSRX mentioned in Kresmion daily briefs
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in NSRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NSRX in the last 180 days.
Upstream: SEC EDGAR filings for NSRX
Kresmion, "Nasus Pharma Ltd (NSRX) institutional holdings and SEC filings", data as of 2026-10-08, https://kresmion.com/research/NSRX. Upstream data: SEC EDGAR filings for NSRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/NSRX">Nasus Pharma Ltd (NSRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow NSRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NSRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.